CoChat

Aldosterone: Direct Effects on and Production by the Heart

White, Perrin C. · 2003 · The Journal of Clinical Endocrinology & Metabolism
Cited by 97

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

The main effects of aldosterone, the most physiologically important mineralocorticoid, are on electrolyte transport across epithelia, particularly in the kidney, but also in other tissues, such as salivary glands and colon. Aldosterone acts to increase sodium (and consequently water) resorption and potassium excretion by directly or indirectly increasing the activity of epithelial sodium channels and sodium, potassium-adenosine triphosphatase (1). Aldosterone excess, whether from genetic causes or primary aldosteronism (hyperplasia or aldosterone-secreting adenomas), is well documented to cause hypertension. Hypertension, in turn, has significant adverse effects on the cardiovascular system, including left ventricular hypertrophy and cardiac fibrosis. Clinical evidence has been accumulating at an accelerating rate suggesting that aldosterone has direct adverse effects on the heart that are independent of its effects on blood pressure. Patients with primary aldosteronism are more likely to have left ventricular hypertrophy and stroke than patients with essential hypertension of comparable severity. More importantly, patients with severe heart failure have a 30% reduction in morbidity and mortality when given a mineralocorticoid receptor antagonist, spironolactone, in addition to conventional therapy of an angiotensin-converting enzyme (ACE) inhibitor, digoxin, and furosemide. The dose of spironolactone used in this study (25 mg) had no incremental effect on blood pressure, suggesting a direct cardioprotective effect (2). Remarkably, spironolactone had a significant beneficial effect only in patients with above median baseline levels of a marker of collagen synthesis, procollagen type III amino-terminal peptide. Elevated baseline levels of this peptide were associated with an increased risk of death and hospitalization, and circulating levels were decreased by spironolactone treatment. These results suggest that the limitation of cardiac fibrosis may be one of mechanisms by which spironolactone benefits patients with congestive heart failure (3).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2003-030373

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 97

Metadata

Authors
White, P. C.
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2003-06-01
Volume
88
Issue
6
Pages
2376-2383
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2030020451
Cited by
97
References
2
FWCI
6.35
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Aldosterone: Direct Effects on and Production by the Heart. https://app.cochat.ai/papers/10.1210/jc.2003-030373
The paper
White, P. C. (2003). Aldosterone: Direct Effects on and Production by the Heart. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2003-030373

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.